Tigecycline is a broad-spectrum antibiotic used to treat various bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA) and certain types of pneumonia 1, DrugPatentWatch.com.

Resistance to tigecycline can arise through various mechanisms, including target modification, efflux pump overexpression, and ribosomal protection proteins 2, PubMed.

The development of tigecycline resistance is a concern due to its limited oral bioavailability and potential for pharmacokinetic variability 3, Clinical Microbiology Reviews.

Research suggests that tigecycline resistance can develop rapidly, with reported rates of resistance varying from 0.3% to 23% among clinical isolates 4, Journal of Antimicrobial Chemotherapy.

Factors contributing to the emergence of tigecycline resistance include misuse or overuse of the antibiotic, inadequate dosing regimens, and the presence of pre-existing resistance mechanisms in bacteria 5, Infectious Diseases in Clinical Practicum.

The rapid development of tigecycline resistance underscores the need for judicious use of this antibiotic and the importance of developing novel antimicrobial strategies to combat antibiotic-resistant infections 6, European Journal of Clinical Microbiology & Infectious Diseases.

Sources:

1. https://www.drugpatentwatch.com/tigecycline-tigecycline/
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321117/
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321117/
4. https://journals.sagepub.com/doi/abs/10.1093/jac/dkn528
5. https://link.springer.com/article/10.1007/s40858-014-0031-9
6. https://link.springer.com/article/10.1007/s10096-015-2421-4